Smith & Nephew plc 11.2% Potential Decrease Indicated by Goldman Sachs

Broker Ratings

Smith & Nephew plc using EPIC/TICKER code (LON:SN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘NEUTRAL’ today by analysts at Goldman Sachs. Smith & Nephew plc are listed in the Health Care sector within UK Main Market. Goldman Sachs have set their target price at 1670 GBX on its stock. This now indicates the analyst believes there is a potential downside of -11.2% from today’s opening price of 1880 GBX. Over the last 30 and 90 trading days the company share price has increased 109 points and increased 30.5 points respectively. The 1 year high for the stock price is 1998.4 GBX while the 52 week low for the share price is 1402 GBX.

Smith & Nephew plc has a 50 day moving average of 1,759.66 GBX and the 200 Day Moving Average price is recorded at 1,768.15. There are currently 875,070,623 shares in issue with the average daily volume traded being 2,166,540. Market capitalisation for LON:SN is £16,471,542,741 GBP.

Share on:
Find more news, interviews, share price & company profile here for:
    Smith & Nephew's Q3 2024 update shows a 4% revenue growth to $1,412M. Despite China headwinds, US Orthopaedics and Sports Medicine excelled.
    Smith & Nephew plc (LON:SN, NYSE:SNN) reports a robust financial performance for Q2 and H1 2024, showing significant revenue and profit growth.
    Smith+Nephew plc (LON:SN, NYSE:SNN) reports Q1 revenue of $1,386 million, up 2.9% underlying. Orthopaedics and Sports Medicine show strong growth. CEO confident in outlook.
    Smith+Nephew plc reports solid financial results for Q4 and full year 2023, showcasing growth in revenue and profit margins. Analyst call scheduled for 27 Feb 2024.
    Smith+Nephew plc (LON:SN, NYSE:SNN) will be attending AAOS 2024 Annual Meeting to showcase its innovative medical technology solutions in San Francisco. Learn about their latest products and updates in the orthopaedic field.

      Search

      Search